Mycobacterial ethambutol responsive genes and implications in antibiotics resistance

References

• Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012;90(2):111–119D.
   PubMed Web of Science ®Google Scholar
• Sethi S, Mewara A, Dhatwalia SK, et al. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis. 2013;13:137.
   PubMed Web of Science ®Google Scholar
• Global tuberculosis report; 2019. Available from: https://www.who.int/publications/i/item/global-tuberculosis-report-2019
   Google Scholar
• Wilson TM. Clinical experience with ethambutol. Antibiot Chemother. 1970;16:222–229.
   PubMedGoogle Scholar
• Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med. 1993;329(12):898–904.
   PubMed Web of Science ®Google Scholar
• Thomas JP, Baughn CO, Wilkinson RG, et al. A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2′-(ethylenediimino)-di-l-butanol). Am Rev Respir Dis. 1961;83:891–893.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Mokaddas E, Al-Mutairi N, et al. Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country. PLoS One. 2016;11(4):e0153563.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb). 2007;87(2):123–129.
   PubMed Web of Science ®Google Scholar
• Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med. 1997;3(5):567–570.
   PubMed Web of Science ®Google Scholar
• Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A. 1996;93(21):11919–11924.
   PubMed Web of Science ®Google Scholar
• Cheng S, Cui Z, Li Y, et al. Diagnostic accuracy of a molecular drug susceptibility testing method for the antituberculosis drug ethambutol: a systematic review and meta-analysis. J Clin Microbiol. 2014;52(8):2913–2924.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics of ethambutol; 2020. Available from: http://drugs.medlive.cn/drugref/html/14405.shtml
   Google Scholar
• Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8(11):1360–1367.
   PubMed Web of Science ®Google Scholar
• Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis. 2005;41(11):1638–1647.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170–1177.
   PubMed Web of Science ®Google Scholar
• Talbert Estlin KA, Sadun AA. Risk factors for ethambutol optic toxicity. Int Ophthalmol. 2010;30(1):63–72.
   PubMedGoogle Scholar
• Martin SJ, Bowden FJ. Ethambutol toxicity manifesting as acute onset psychosis. Int J STD Aids. 2007;18(4):287–288.
   PubMed Web of Science ®Google Scholar
• Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006;12(1):56–60.
   PubMedGoogle Scholar
• Chung H, Yoon YH, Hwang JJ, et al. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 2009;235(2):163–170.
   PubMed Web of Science ®Google Scholar
• Yoon YH, Jung KH, Sadun AA, et al. Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol. 2000;162(2):107–114.
   PubMed Web of Science ®Google Scholar
• Tsai RK, Chang CH, Hseu CM, et al. Ethambutol induces PKC-dependent cytotoxic and antiproliferative effects on human retinal pigment cells. Exp Eye Res. 2008;87(6):594–603.
   PubMed Web of Science ®Google Scholar
• Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol. 1997;1(4):579–588.
   PubMed Web of Science ®Google Scholar
• Jankute M, Grover S, Rana AK, et al. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol. 2012;7(1):129–147.
   PubMed Web of Science ®Google Scholar
• Mikusova K, Slayden RA, Besra GS, et al. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother. 1995;39(11):2484–2489.
   PubMed Web of Science ®Google Scholar
• Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1989;33(9):1493–1499.
   PubMed Web of Science ®Google Scholar
• Alderwick LJ, Radmacher E, Seidel M, et al. Deletion of Cg-emb in Corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiA results in an arabinan-deficient mutant with a cell wall galactan core. J Biol Chem. 2005;280(37):32362–32371.
   PubMed Web of Science ®Google Scholar
• Berg S, Starbuck J, Torrelles JB, et al. Roles of conserved proline and glycosyltransferase motifs of EmbC in biosynthesis of lipoarabinomannan. J Biol Chem. 2005;280(7):5651–5663.
   PubMed Web of Science ®Google Scholar
• Escuyer VE, Lety MA, Torrelles JB, et al. The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem. 2001;276(52):48854–48862.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ayyagari A, Dhole TN, et al. emb nucleotide polymorphisms and the role of embB306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol. 2009;299(4):269–280.
   PubMed Web of Science ®Google Scholar
• Zhao LL, Sun Q, Liu HC, et al. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates from China. Antimicrob Agents Chemother. 2015;59(4):2045–2050.
   PubMed Web of Science ®Google Scholar
• Park YK, Ryoo SW, Lee SH, et al. Correlation of the phenotypic ethambutol susceptibility of Mycobacterium tuberculosis with embB gene mutations in Korea. J Med Microbiol. 2012;61(Pt 4):529–534.
   PubMed Web of Science ®Google Scholar
• Tessema B, Beer J, Emmrich F, et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012;12:37.
   PubMed Web of Science ®Google Scholar
• Chaoui I, Sabouni R, Kourout M, et al. Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco. J Infect Dev Ctries. 2009;3(4):278–284.
   PubMed Web of Science ®Google Scholar
• Sugawara I, Otomo K, Yamada H, et al. The molecular epidemiology of ethambutol-resistant Mycobacterium tuberculosis in Henan Province, China. Jpn J Infect Dis. 2005;58(6):393–395.
   PubMed Web of Science ®Google Scholar
• Jadaun GP, Das R, Upadhyay P, et al. Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India. Int J Antimicrob Agents. 2009;33(5):483–486.
   PubMed Web of Science ®Google Scholar
• Plinke C, Cox HS, Zarkua N, et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J Antimicrob Chemother. 2010;65(7):1359–1367.
   PubMed Web of Science ®Google Scholar
• Safi H, Sayers B, Hazbon MH, et al. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother. 2008;52(6):2027–2034.
   PubMed Web of Science ®Google Scholar
• Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, et al. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):331–342.
   PubMed Web of Science ®Google Scholar
• Safi H, Fleischmann RD, Peterson SN, et al. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010;54(1):103–108.
   PubMed Web of Science ®Google Scholar
• Cuevas-Cordoba B, Juarez-Eusebio DM, Almaraz-Velasco R, et al. Mutation at embB codon 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(9):5455–5462.
   PubMed Web of Science ®Google Scholar
• Sreevatsan S, Stockbauer KE, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother. 1997;41(8):1677–1681.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi NM, Ahmad S, Mokaddas E. Molecular screening versus phenotypic susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates for streptomycin and ethambutol. Microb Drug Resist. 2018;24(7):923–931.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jia H, Huang H, et al. Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and -resistant Mycobacterium tuberculosis clinical isolates from China. Biomed Res Int. 2015;2015:951706.
   PubMed Web of Science ®Google Scholar
• Ramaswamy SV, Amin AG, Goksel S, et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44(2):326–336.
   PubMed Web of Science ®Google Scholar
• Brossier F, Sougakoff W, Bernard C, et al. Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2015;59(8):4800–4808.
   PubMed Web of Science ®Google Scholar
• Cui Z, Li Y, Cheng S, et al. Mutations in the embC–embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob Agents Chemother. 2014;58(11):6837–6843.
   PubMed Web of Science ®Google Scholar
• Moure R, Espanol M, Tudo G, et al. Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array-authors' response. J Antimicrob Chemother. 2014;69(8):2299–2300.
   PubMed Web of Science ®Google Scholar
• Weiling H, Xiaowen Y, Chunmei L, et al. Function and evolution of ubiquitous bacterial signaling adapter phosphopeptide recognition domain FHA. Cell Signal. 2013;25(3):660–665.
   PubMed Web of Science ®Google Scholar
• Sharma K, Gupta M, Krupa A, et al. EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in Mycobacterium tuberculosis. FEBS J. 2006;273(12):2711–2721.
   PubMed Web of Science ®Google Scholar
• Alderwick LJ, Molle V, Kremer L, et al. Molecular structure of EmbR, a response element of Ser/Thr kinase signaling in Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2006;103(8):2558–2563.
   PubMed Web of Science ®Google Scholar
• Molle V, Reynolds RC, Alderwick LJ, et al. EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR. Biochem J. 2008;410(2):309–317.
   PubMedGoogle Scholar
• Sharma K, Gupta M, Pathak M, et al. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. J Bacteriol. 2006;188(8):2936–2944.
   PubMed Web of Science ®Google Scholar
• Song N, Li Z, Cui Z, et al. The prominent alteration in transcriptome and metabolome of Mycobacterium bovis BCG str. Tokyo 172 induced by vitamin B1. BMC Microbiol. 2019;19(1):104.
   PubMedGoogle Scholar
• Betts JC, McLaren A, Lennon MG, et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47(9):2903–2913.
   PubMed Web of Science ®Google Scholar
• Fu LM. Exploring drug action on Mycobacterium tuberculosis using affymetrix oligonucleotide genechips. Tuberculosis (Edinb). 2006;86(2):134–143.
   PubMed Web of Science ®Google Scholar
• Jeeves RE, Marriott AA, Pullan ST, et al. Mycobacterium tuberculosis is resistant to isoniazid at a slow growth rate by single nucleotide polymorphisms in katG codon Ser315. PLoS One. 2015;10(9):e0138253.
   PubMed Web of Science ®Google Scholar
• Jousselin A, Renzoni A, Andrey DO, et al. The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(7):3629–3640.
   PubMed Web of Science ®Google Scholar
• Munoz-Elias EJ, Upton AM, Cherian J, et al. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol. 2006;60(5):1109–1122.
   PubMed Web of Science ®Google Scholar
• Tang S, Hicks ND, Cheng YS, et al. Structural and functional insight into the Mycobacterium tuberculosis protein PrpR reveals a novel type of transcription factor. Nucleic Acids Res. 2019;47(18):9934–9949.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li D, Zhao L, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013;45(10):1255–1260.
   PubMed Web of Science ®Google Scholar
• Honeyborne I, McHugh TD, Kuittinen I, et al. Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Med. 2016;14:68.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu F, Chen S, et al. In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment. BMC Genomics. 2018;19(1):640.
   PubMedGoogle Scholar
• Dubey VS, Sirakova TD, Cynamon MH, et al. Biochemical function of msl5 (pks8 plus pks17) in Mycobacterium tuberculosis H37Rv: biosynthesis of monomethyl branched unsaturated fatty acids. J Bacteriol. 2003;185(15):4620–4625.
   PubMed Web of Science ®Google Scholar
• Chiarelli LR, Mori G, Orena BS, et al. A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. Sci Rep. 2018;8(1):3187.
   PubMedGoogle Scholar
• Ramon-Garcia S, Mick V, Dainese E, et al. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother. 2012;56(4):2074–2083.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang W, Zhang Y, et al. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist. 2008;14(1):7–11.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Katoch VM, Chauhan DS, et al. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist. 2010;16(1):21–28.
   PubMed Web of Science ®Google Scholar
• Fikret Şahinkiyan M. The roles of efflux systems in extensively drug-resistant Mycobacterium tuberculosis. Turk J Mol Biol Biotechnol. 2017;2:71–81.
   Google Scholar
• Pisu D, Provvedi R, Espinosa DM, et al. The alternative sigma factors SigE and SigB are involved in tolerance and persistence to antitubercular drugs. Antimicrob Agents Chemother. 2017;61(12):AAC.01596-17.
   Web of Science ®Google Scholar
• Duncan C, Jamieson FB, Troudt J, et al. Whole transcriptomic and proteomic analyses of an isogenic M. tuberculosis clinical strain with a naturally occurring 15 Kb genomic deletion. PLoS One. 2017;12(6):e0179996.
   PubMed Web of Science ®Google Scholar
• Skvortsov TA, Ignatov DV, Majorov KB, et al. Mycobacterium tuberculosis transcriptome profiling in mice with genetically different susceptibility to tuberculosis. Acta Nat. 2013;5(2):62–69.
   PubMed Web of Science ®Google Scholar
• Huang H, Berg S, Spencer JS, et al. Identification of amino acids and domains required for catalytic activity of DPPR synthase, a cell wall biosynthetic enzyme of Mycobacterium tuberculosis. Microbiology (Reading). 2008;154(Pt 3):736–743.
   PubMedGoogle Scholar
• Lingaraju S, Rigouts L, Gupta A, et al. Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(7):4101–4105.
   PubMed Web of Science ®Google Scholar
• Safi H, Lingaraju S, Amin A, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-d-arabinose biosynthetic and utilization pathway genes. Nat Genet. 2013;45(10):1190–1197.
   PubMed Web of Science ®Google Scholar
• He L, Wang X, Cui P, et al. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2015;95(2):149–154.
   PubMed Web of Science ®Google Scholar
• Wang M, Guo X, Yang X, et al. Mycobacterial dynamin-like protein IniA mediates membrane fission. Nat Commun. 2019;10(1):3906.
   PubMedGoogle Scholar
• Ahmad S, Mokaddas E, Jaber AA. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes. 2004;18(5):299–306.
   PubMed Web of Science ®Google Scholar
• Jaber AA, Ahmad S, Mokaddas E. Minor contribution of mutations at iniA codon 501 and embC–embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Ann Clin Microbiol Antimicrob. 2009;8:2.
   PubMed Web of Science ®Google Scholar
• Wang R, Marcotte EM. The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways. J Proteome Res. 2008;7(3):855–865.
   PubMed Web of Science ®Google Scholar
• Boshoff HI, Myers TG, Copp BR, et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem. 2004;279(38):40174–40184.
   PubMed Web of Science ®Google Scholar
• Ojha A, Anand M, Bhatt A, et al. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell. 2005;123(5):861–873.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhan Y, Sun M, et al. The novel responses of ethambutol against Mycobacterium smegmatis mc2155 revealed by proteomics analysis. Curr Microbiol. 2011;62(2):341–345.
   PubMed Web of Science ®Google Scholar
• Gorla P, Plocinska R, Sarva K, et al. MtrA response regulator controls cell division and cell wall metabolism and affects susceptibility of mycobacteria to the first line antituberculosis drugs. Front Microbiol. 2018;9:2839.
   PubMed Web of Science ®Google Scholar
• Brocker M, Bott M. Evidence for activator and repressor functions of the response regulator MtrA from Corynebacterium glutamicum. FEMS Microbiol Lett. 2006;264(2):205–212.
   PubMed Web of Science ®Google Scholar
• Moker N, Brocker M, Schaffer S, et al. Deletion of the genes encoding the MtrA–MtrB two-component system of Corynebacterium glutamicum has a strong influence on cell morphology, antibiotics susceptibility and expression of genes involved in osmoprotection. Mol Microbiol. 2004;54(2):420–438.
   PubMed Web of Science ®Google Scholar